Cure8 research brief
Fungi in the gut appear to influence immune pathways implicated in IBD and other autoimmune diseases, suggesting new therapeutic targets and microbiome-based interventions that could affect disease activity.
Researchers, clinicians, and patients interested in the gut microbiome, immunology, and emerging IBD therapies
The paper reviews basic science and clinical studies linking commensal fungi (Candida, Saccharomyces, Malassezia) to both pro- and anti-inflammatory immune pathways, including Dectin/Syk-CARD9, Toll-like receptors, NF-κB, inflammasomes, Th17 and Treg responses.
Animal models and some clinical trials suggest that manipulating the mycobiome (probiotic yeasts, fungal cell-wall components) can alter disease activity in IBD and other autoimmune conditions, but findings are heterogeneous and mechanism-focused. This is a review article (abstract-level summary provided here).
It synthesizes existing preclinical and clinical literature rather than reporting a new trial. It highlights potential therapeutic targets (fungal metabolites, cell-wall ligands) that may inform future drug development or probiotic strategies, but does not establish clinical recommendations.
This is a review article synthesizing preclinical and clinical studies; it does not present new trial results. Clinical evidence is promising but not definitive.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The review highlights how microbial metabolites, epigenetic regulation, and mitochondrial metabolism interact to shape inflammation and barrier function in IBD. Understanding these links could help identify new...
This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...
The review brings together evidence that genetics, immune responses, the gut microbiome, and environmental triggers interact to cause Crohn's disease and ulcerative colitis.
